Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase (Q34001339)

30 July 2017

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase (English)

1 reference

30 July 2017

Zhengying Pan

1

1 reference

30 July 2017

Heleen Scheerens

2

1 reference

30 July 2017

Shyr-Jiann Li

3

1 reference

30 July 2017

Brian E Schultz

4

1 reference

30 July 2017

Paul A Sprengeler

5

1 reference

30 July 2017

L Chuck Burrill

6

1 reference

30 July 2017

Rohan V Mendonca

7

1 reference

30 July 2017

Michael D Sweeney

8

1 reference

30 July 2017

Keana C K Scott

9

1 reference

30 July 2017

Paul G Grothaus

10

1 reference

30 July 2017

Douglas A Jeffery

11

1 reference

30 July 2017

Jill M Spoerke

12

1 reference

30 July 2017

Lee A Honigberg

13

1 reference

30 July 2017

Peter R Young

14

1 reference

30 July 2017

Stacie A Dalrymple

15

1 reference

30 July 2017

James T Palmer

16

1 reference

30 July 2017

1 January 2007

1 reference

30 July 2017

1 reference

30 July 2017

2

1 reference

30 July 2017

1

1 reference

30 July 2017

58-61

1 reference

Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes

30 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

Tec kinases: modulators of lymphocyte signaling and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Structural bioinformatics-based design of selective, irreversible kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Structural basis for selective inhibition of Src family kinases by PP1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Irreversible inhibitors of the erbB family of protein tyrosine kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Features of selective kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Therapeutic strategies for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600221

7 January 2021

Identifiers

DOI

10.1002/CMDC.200600221

1 reference

release_34jbtmchlnelzoamvjvyeatn5m

30 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/34jbtmchlnelzoamvjvyeatn5m

24 November 2022

mapped directly with Wikidata item

1 reference